Voyager Therapeutics

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

At Voyager Therapeutics, we are dedicated to leveraging our innovative and proprietary gene delivery platforms to bring life-changing therapies to those suffering from devastating neurological diseases.

The Voyager team is working to develop state-of-the-art treatments for severe neurological diseases that until now have lacked effective treatments. We strive to bring relief and a better quality of life to those suffering from diseases such as Parkinson's Disease, Huntington's Disease, and other neurological conditions.

Voyager has been recognized numerous times for its groundbreaking research and technology, most recently winning the 2017 Breakthrough Prize in Life Sciences and being named an Edison Award finalist in 2016.